When endometrial cancer spreads beyond the uterus to distant parts of the body, managing the disease becomes more complex, but treatment options continue to evolve with the goal of controlling symptoms, slowing progression, and improving quality of life for patients.

Understanding Treatment Goals for Advanced Disease

Metastatic endometrial cancer represents a stage where cancer cells that originated in the lining of the uterus have traveled to other organs, most commonly the lungs, liver, bones, or brain. While this advanced stage is not considered curable, the landscape of treatment has changed significantly in recent years. The primary goals of therapy shift toward controlling the spread of cancer, reducing symptoms that affect daily living, and extending survival time as much as possible.^[1]

Treatment decisions depend heavily on where the cancer has spread, how much disease is present, and the overall health of the patient. Around 10 to 15 percent of people with endometrial cancer are diagnosed after the disease has already reached distant body parts, making early and appropriate intervention critical.^[1] Because each person’s situation is unique, specialists called gynecologic oncologists—doctors who focus specifically on cancers of the female reproductive system—play a central role in crafting individualized treatment plans.^[1]

The treatment approach for metastatic endometrial cancer is multimodal, meaning it often combines several methods. Standard treatments approved by medical societies include surgery, radiation therapy, and various drug therapies. At the same time, researchers are actively investigating new therapies through clinical trials, offering hope for better outcomes and more targeted approaches in the future.^[2]

Standard Treatment Approaches

Surgery remains the cornerstone of treatment for endometrial cancer, even in advanced cases. When possible, doctors perform a hysterectomy, which means removing the uterus, along with removal of the fallopian tubes and ovaries in a procedure called salpingo-oophorectomy. In metastatic disease, surgeons may also remove lymph nodes in the pelvic area or attempt to remove as much visible cancer as possible, a process known as cytoreductive surgery or debulking.^[2][4] The goal is to reduce the overall tumor burden in the body, which can help other treatments work better and may improve survival.

Following surgery, or sometimes as the primary treatment when surgery is not possible, radiation therapy becomes an important tool. Radiation uses high-energy beams to destroy cancer cells or stop them from growing. It can be delivered externally through a machine that targets specific areas of the body, or internally through a technique called brachytherapy, where radioactive material is placed inside or near the tumor. Radiation is particularly useful for treating cancer that has spread to nearby structures like the bladder or bowel, or to address symptoms such as pain or bleeding.^[9][10]

For metastatic disease, chemotherapy is frequently used. Chemotherapy refers to drugs that kill rapidly dividing cancer cells throughout the body. Since metastatic cancer has spread through the bloodstream or lymphatic system to distant sites, systemic treatment—meaning treatment that affects the entire body—becomes necessary. Common chemotherapy drugs used in endometrial cancer include paclitaxel, carboplatin, and doxorubicin. These drugs may be given alone or in combination, depending on the specific situation.^[10][12]

Another standard treatment option is hormone therapy. Because some endometrial cancers are driven by hormones like estrogen, drugs that block hormone activity can slow cancer growth. This approach works best for tumors that have receptors for estrogen or progesterone. Hormone therapies include progestins such as megestrol acetate or medroxyprogesterone, which are synthetic versions of the hormone progesterone. Hormone therapy tends to have fewer side effects than chemotherapy and can be particularly useful for patients who cannot tolerate more aggressive treatments.^[4][10]

More recently, targeted therapy has entered the treatment landscape. These are drugs designed to attack specific features of cancer cells, such as proteins or pathways that help the cancer grow and spread. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies aim to be more precise, potentially causing fewer side effects. However, their use depends on the presence of specific markers in the tumor, which must be identified through laboratory testing.^[4][10]

The duration of therapy varies widely. Some patients receive chemotherapy for a set number of cycles—often six to eight courses given every few weeks. Others may continue hormone therapy for months or even years as long as it controls the disease and side effects remain manageable. Radiation is typically delivered over several weeks in daily sessions.^[10][12]

Side effects are an important consideration with any treatment. Chemotherapy can cause nausea, vomiting, hair loss, fatigue, and increased risk of infection due to effects on the immune system. Radiation may lead to skin irritation, fatigue, and damage to nearby organs depending on where it is directed. Hormone therapy can cause weight gain, fluid retention, and mood changes. Targeted therapies may produce different side effects depending on the specific drug used, including high blood pressure, diarrhea, or liver problems. Discussing potential side effects and how to manage them is an essential part of treatment planning.^[2][4]

Treatment in Clinical Trials

Clinical trials represent the forefront of cancer treatment research. These are carefully controlled studies that test new drugs, combinations of drugs, or entirely new treatment approaches before they become widely available. For patients with metastatic endometrial cancer, participating in a clinical trial may provide access to promising therapies that could be more effective than current standard treatments.^[2]

Clinical trials are conducted in phases, each designed to answer specific questions. Phase I trials focus primarily on safety. Researchers determine the appropriate dose of a new drug and identify what side effects occur. These trials typically involve a small number of participants. Phase II trials expand to more patients and evaluate whether the treatment actually works—does it shrink tumors, slow cancer growth, or improve symptoms? Phase III trials are large studies that compare the new treatment directly to the current standard of care to determine if the new approach is better, equivalent, or inferior. Phase IV trials continue to monitor a treatment after it has been approved to gather information about long-term effects and optimal use in broader populations.

One area of active investigation in metastatic endometrial cancer involves immunotherapy. Immunotherapy works by helping the body’s own immune system recognize and attack cancer cells. Cancer cells often hide from the immune system by using proteins that act like “off switches.” Drugs called checkpoint inhibitors block these proteins, allowing immune cells to see and destroy the cancer. Examples include pembrolizumab and dostarlimab, which target a protein called PD-1. These drugs have shown promise particularly in endometrial cancers with specific molecular features, such as defects in DNA mismatch repair, a condition known as microsatellite instability or mismatch repair deficiency.^[4][12]

Preliminary results from trials testing checkpoint inhibitors have been encouraging. Some patients experience significant tumor shrinkage and improved survival, and in certain cases, these responses can be durable, lasting for extended periods. The side effects of immunotherapy differ from chemotherapy and can include immune-related reactions such as inflammation of the lungs, liver, intestines, or other organs, requiring careful monitoring.^[12]

Another innovative approach being tested involves combinations of targeted therapies. Scientists have identified several molecular pathways that cancer cells depend on for growth. For instance, some drugs target enzymes involved in cell division or blood vessel formation that feeds tumors. Combining these targeted agents with chemotherapy or immunotherapy is under investigation to see if the combination is more effective than either treatment alone.

Some clinical trials are exploring the use of drugs that attack cancer cells based on specific genetic mutations. For example, cancers with mutations in genes such as PIK3CA or alterations in the mTOR pathway may respond to drugs designed to block these abnormal signals. Identifying these mutations requires molecular testing of the tumor, sometimes called biomarker-directed therapy.^[10][12]

Clinical trials for endometrial cancer are conducted in many locations, including major cancer centers in the United States, Europe, and other regions around the world. Some trials are specific to certain types or stages of endometrial cancer, while others may be open to various solid tumors with particular molecular features. Information about ongoing trials can be found through cancer research organizations and hospital networks.

Most common treatment methods

• Surgery
  • Hysterectomy (removal of the uterus) combined with bilateral salpingo-oophorectomy (removal of fallopian tubes and ovaries)
  • Lymph node removal in pelvic and sometimes abdominal areas
  • Cytoreductive or debulking surgery to remove as much visible cancer as possible in metastatic disease
• Radiation Therapy
  • External beam radiation therapy directed at areas of cancer spread
  • Brachytherapy, where radioactive material is placed inside or near the tumor
  • Used to control symptoms such as pain or bleeding, or to treat cancer in specific locations like bladder or bowel
• Chemotherapy
  • Systemic drugs such as paclitaxel, carboplatin, and doxorubicin used alone or in combination
  • Delivered through the bloodstream to reach cancer cells throughout the body
  • Typically given in cycles over several months
• Hormone Therapy
  • Progestins including megestrol acetate and medroxyprogesterone
  • Works best in tumors with estrogen or progesterone receptors
  • May be used for long periods with generally fewer side effects than chemotherapy
• Targeted Therapy
  • Drugs designed to attack specific proteins or pathways in cancer cells
  • Use depends on presence of specific markers identified through tumor testing
  • Part of biomarker-directed treatment strategies
• Immunotherapy (in clinical trials and recent approvals)
  • Checkpoint inhibitors such as pembrolizumab and dostarlimab that block PD-1 protein
  • Help the immune system recognize and attack cancer cells
  • Particularly effective in tumors with microsatellite instability or mismatch repair deficiency